Satsuma Pharmaceuticals, Inc.
STSA · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | 0.41 | -0.50 |
| FCF Yield | -49.16% | -41.02% | -7.02% | -9.18% |
| EV / EBITDA | -0.37 | -1.19 | -10.08 | -6.64 |
| Quality | ||||
| ROIC | -27.20% | -48.88% | -22.08% | -22.47% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.11 | 0.52 | 0.89 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 6.92% | 8.85% | -11.85% | 16.34% |
| Safety | ||||
| Net Debt / EBITDA | 1.89 | 1.43 | 2.70 | 1.46 |
| Interest Coverage | 22.72 | 0.00 | -57.28 | -8,200.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |